Rani Therapeutics Holdings, Inc. (RANI)

6,68 +0,12 (+1,83%) Börsenschluss: 04:00PM EDT

Rani Therapeutics Holdings, Inc.

2051 Ringwood Avenue
San Jose, CA 95131
United States
408 457 3700
https://www.ranitherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 140

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Mir A. Imran	Executive Chairman	80k	N/A	1957
Mr. Talat Imran	CEO & Director	450k	N/A	1982
Mr. Svai S. Sanford	Chief Financial Officer	416k	N/A	1970
Dr. Mir Hashim	Chief Scientific Officer	416k	N/A	1960
Mr. Eric Groen	General Counsel	N/A	N/A	1971
Ms. Bella Vazquez	Vice President of Human Resources	N/A	N/A	N/A
Ms. Kate McKinley M.B.A.	Chief Business Officer	N/A	N/A	1977
Ms. Arvinder Dhalla	Vice President of Clinical Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Corporate Governance

Rani Therapeutics Holdings, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.